Merck & Co., Inc. $MRK Shares Sold by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 4.5% during the 3rd quarter, Holdings Channel reports. The fund owned 103,510 shares of the company’s stock after selling 4,916 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $15,041,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in MRK. Round Rock Advisors LLC increased its position in Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after buying an additional 66 shares during the period. Cascade Financial Partners LLC boosted its position in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after acquiring an additional 80 shares during the period. Somerset Trust Co boosted its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after acquiring an additional 81 shares during the period. Stonebridge Financial Group LLC boosted its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after acquiring an additional 81 shares during the period. Finally, Stronghold Wealth Management L.L.C. boosted its position in shares of Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after acquiring an additional 82 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. UBS Group upped their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wolfe Research lifted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 25th. Morgan Stanley cut their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. Finally, Leerink Partners increased their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $146.01 on Friday. The stock has a market capitalization of $360.22 billion, a PE ratio of 116.81, a P/E/G ratio of 6.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The business has a fifty day moving average price of $145.60 and a two-hundred day moving average price of $129.24. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Insiders Place Their Bets

In related news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Richard Deluca sold 20,784 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 over the last 90 days. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.